Thymosin Beta-4 (TB-500)

Overview

Thymosin beta-4 (Tβ4) is a naturally occurring, highly conserved protein present in nearly all mammalian cells, best known for its role in regulating actin polymerization within the cytoskeleton. "TB-500" is a name commonly used in the research-chemical market for a shorter synthetic peptide intended to reproduce the active region of the full Tβ4 protein. Note that most of the foundational published literature — including both studies cited here — was conducted on the naturally occurring full-length Tβ4 protein, not the shortened TB-500 fragment specifically; researchers should not assume the two are pharmacologically identical.

Proposed Mechanism of Action

Tβ4 is implicated in cell migration, angiogenesis, and reduced inflammation in wound sites. Philp et al. (2004) summarize evidence that Tβ4 promotes keratinocyte migration and new blood vessel formation in rodent wound-healing models. Tokura et al. (2011) demonstrate that Tβ4 released after muscle injury acts as a chemoattractant, drawing myoblasts (muscle precursor cells) toward the site of damage in mice.

Research Context

These are mechanistic and applied animal studies, not human clinical trials. Because thymosin beta-4 is an endogenous protein rather than a novel synthetic compound, much of the literature focuses on characterizing its natural role in injury response rather than establishing an exogenous dosing protocol.

Dosing Data

We have not found abstract-level dosing figures (dose, route, frequency) in the two studies cited above sufficient to responsibly reproduce here — the relevant methodology is in the full-text methods sections, which we have not yet reviewed in full. Rather than approximate, this section is intentionally left without a dosing table. If you have access to the full text and can verify exact figures, that data should replace this note.

Limitations of the Current Evidence

• Much of the available literature concerns the naturally occurring full-length protein rather than the shortened synthetic fragment marketed as "TB-500," and the two should not be assumed equivalent.
• No dosing protocol has been established here from verified primary sources; treat any third-party dosing claims for TB-500 with skepticism until traced to a primary source.